Abstract
The D2 or D1 dopamine receptor blockers (−)-sulpiride or SCH 23390 antagonized, in a dose dependent manner, the hypermotility induced by the N-methyl-d-aspartate (NMDA) receptor antagonist, MK-801 (0.25 mg/kg IP). MK-801 induced hyperactivity was not detected when rats were observed on days 7, 14 or 21 of 21 daily injections of MK-801. This lack of hyperactivity was also noted 5 days after the last administration of the repeated treatment with MK-801. The hypermotility induced by the D2 dopamine receptor agonist LY 171555 (0.3 mg/kg IP) was reduced 5 days following repeated treatment (21 days) with MK-801, while no change in the behavioral responses to the selective D1 agonist, SKF 38393, or the mixed D1/D2 agent apomorphine was detected. The results, although suggesting the involvement of dopaminergic pathways in the behavioral effect of MK-801, are conflicting with regard to the underlying mechanisms and to the adaptive changes of dopaminergic system following repeated NMDA receptor blockade.
Similar content being viewed by others
References
Carlsson M, Carlsson A (1989a) The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. J Neural Transm 75:221–226
Carlsson M, Carlsson A (1989b) Dramatic synergism between MK-801 and clonidine with respect to locomotor stimulatory effect in monoamine-depleted mice. J Neural Transm 77:65–71
Carlsson M, Svensson A (1990) Interfering with glutamatergic neurotransmission by means of NMDA administration discloses the locomotor stimulatory potential of other transmitter systems. Pharmacol Biochem Behav 36:45–50
Clineschmidt BV, Martin GE, Bunting PR (1982a) Anticonvulsant activity of (+)-5-methyl-10,11-dihydro-5H-dibenzo(a,d) cyclophepten-5,10-imine (MK-801), a substance with potent anticonvulsant, central sympathomimetic and apparent anxiolitic properties. Drug Dev Res 2:123–134
Clineschmidt BV, Martin GE, Bunting PR, Papp NL (1982b) Central sympathomimetic activity of (+)-5-methyl-10,11-dihydro-5H-dibenzo(a,d) cyclo- phepten-5,10-imine (MK-801), a substance with potent anticonvulsant, central sympathomimetic and apparent anxiolitic properties. Drug Dev Res 2:135–145
Clineschmidt BV, Williams M, Witolslawski JJ, Bunting PR, Risley EA, Totaro JA (1982c) Restoration of shock-suppressed behavior by treatment with (+)-5-methyl-10,11-dihydro-5H-dibenzo(a,d) cyclo- phepten-5,10-imine (MK-801), a substance with potent anticonvulsant, central sympathomimetic and apparent anxiolitic properties. Drug Dev Res 2:147–163
Dall'Olio R, Roncada P, Vaccheri A, Gandolfi O, Montanaro N (1989) Synergistic blockade of some dopamine-mediated behaviors by (−)-sulpiride and SCH 23390 in the rat. Psychopharmacology 98:342–346
Dimpfel W, Spuler M (1990) Dizocilpine (MK-801), ketamine and phencyclidine: low doses affect brain field potentials in the freely moving rat in the same way as activation of dopaminergic transmission. Psychopharmacology 101:317–323
Gandolfi O, Dall'Olio R, Vaccheri A, Roncada P, Montanaro N (1988) Responses to selective D1 and D2 agonists after repeated treatment with selective D1 and D2 antagonists. Pharmacol Biochem Behav 30:463–469
Gill R, Foster AC, Woodruff GN (1987) Systemic administration of MK-801 protects against ischaemia-induced hippocampal neurodegeneration in the gerbil. J Neurosci 7:3343–3349
Hiramatsu M, Cho AK, Nabeshima T (1989) Comparison of the behavioral and biochemical effects of the NMDA receptor antagonists, MK-801 and phencyclidine. Eur J Pharmacol 166:359–366
Iwamoto ET (1986) Comparison of the pharmacologic effects of N-allylnormetazocine and phencyclidine: Sensitization, cross-sensitization, and opioid antagonistic activity. Psychopharmacology 89:221–229
Klawans HL, Margolin DI (1975) Amphetamine-induced dopaminergic hypersensitivity in guinea-pigs. Arch Gen Psychiatry 32:725–732
Liljequist S, Ossowska K, Grabowska-Anden M, Anden NE (1991) Effect of the NMDA receptor antagonist, MK-801, on locomotor activity and on the metabolism of dopamine in various brain areas of mice. Eur J Pharmacol 195:55–61
Oles RJ, Singh L, Tricklebank MD (1990) Differential effects on the behavioural and anticonvulsant properties of MK-801 following repeated administration in the mouse. Br J Pharmacol 99:286P
Rao TS, Kim HS, Lehmann J, Martin LL, Wood PL (1990) Selective activation of dopaminergic pathways in the mesocortex by compounds that act at the phencyclidine (PCP) binding site: tentative evidence for PCP recognition sites not coupled to N-methyl-d-aspartate (NMDA) receptors. Neuropharmacology 29:225–230
Robinson TE, Becker JB (1986) Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res Rev 11:157–198
Segal DS, Mandell AJ (1974) Long-term administration of amphetamine: progressive augmentation of motor activity and stereotypy. Pharmacol Biochem Behav 2:249–255
Wong EHF, Kemp JA, Priestley T, Knight AR, Woodruff GN, Iversen LL (1986) The anticonvulsant MK-801 is a potent N-methyl-d-aspartate antagonist. Proc Natl Acad Sci USA 83:7104–7108
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dall'Olio, R., Gandolfi, O. & Montanaro, N. Effect of chronic treatment with dizocilpine (MK-801) on the behavioral response to dopamine receptor agonists in the rat. Psychopharmacology 107, 591–594 (1992). https://doi.org/10.1007/BF02245275
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02245275